CHICAGO HIGHLIGHTS 2024 – LUNG ROUNDTABLE DISCUSSION: CROWN
OR
Chair
Dr. Barb Melosky
Panelists
Dr. Rosalyn Juergens
Dr. Peter Ellis
This program has been made possible through unrestricted support from Pfizer
Studies/trials discussed:
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
